Fda Approved - Search News

FDA red food dye ban

The Associated Press on MSN · 10h

FDA bans red dye No. 3 from foods

U.S. regulators are banning the dye called Red 3 from the food supply. The move comes nearly 35 years after the dye was barred from cosmetics such as lipsticks because of potential cancer risk.

NBC News on MSN · 15h

FDA bans Red Dye No. 3, artificial coloring used in beverages, candy and other foods

The Food and Drug Administration said Wednesday it’s banning the use of Red No. 3, a synthetic dye that gives food and drinks their bright red cherry color but has been linked to cancer in animals.

USA TODAY on MSN · 11h

FDA bans Red No. 3 food dye in food, drinks: Here's what to know

The FDA announced on Wednesday that it has banned the use of Red No. 3, an additive used to give food and drinks a cherry-red color.

FDA Approves Niktimvo 9 Mg And 22 Mg Vial Sizes

The Wall Street Journal on MSN · 13h

Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s disease, an inflammatory bowel disease that causes chronic abdominal pain.

MarketWatch · 12h

Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes

Incyte has exclusive commercialization rights for Niktimvo outside the U.S. Niktimvo was approved by the FDA on Aug. 14 for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kilograms.

Seeking Alpha on MSN · 11h

Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials

Incyte (NASDAQ:INCY) and Syndax Pharmaceuticals (SNDX) have received FDA approval for their drug Niktimvo in 9 mg and 22 mg vial sizes. Niktimvo was approved in August 2024 for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg,

8hon MSN

US FDA approves expanded use of Lilly's bowel disease drug

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

4d

FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

BioPharma Dive18h

Federal watchdog cites concerns with FDA’s accelerated approval process

The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...

2don MSN

Billed as nonaddictive, new pain pill could soon win FDA approval

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

The Subcutaneous Approval of Opdivo Makes Waves in Future of Cancer Care

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

Hosted on MSN18h

Tempus AI announces national launch of FDA-approved xT CDx test

Tempus AI (TEM) announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx.

21h

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

Attruby's approval makes BridgeBio Pharma a competitor to Vyndaqel, with significant potential for growth and milestone ...

1d

Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results